New drug duo targets hard-to-treat lymphoma
NCT ID NCT07583810
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, nemtabrutinib and rituximab, in about 35 adults with marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the combo is safe and can shrink or eliminate tumors. Participants will receive the drugs by mouth and through an IV, and researchers will monitor side effects and response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONJUNCTIVAL MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can 3D-Printed models unlock personalized blood cancer therapies?
- Can engineered immune cells tackle brain lymphoma?